Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023)
Summit Therapeutics' (SMMT) quarterly Asset Writedowns and Impairment came in at $474000.0 in Q1 2023, down 94.4% on a QoQ basis from $8.5 million in Q4 2022.
Powered by 
Analysis
Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2020 - 2023) Analysis & Trends
Summit Therapeutics (SMMT) has 3 years of Asset Writedowns and Impairment data on file, last reported at $474000.0 in Q1 2023.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $474000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $474000.0 (down 94.4% YoY) and the FY2023 annual result came in at $474000.0, down 94.4% from the prior year.
- Asset Writedowns and Impairment slipped to $474000.0 in Q1 2023, from $8.5 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $8.5 million in Q4 2022 to a low of $474000.0 in Q1 2023.
- A 3-year average of $3.3 million and a median of $859000.0 in 2020 frame the typical range for Asset Writedowns and Impairment.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Summit Therapeutics | 13.67 Bn | 12.98 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 474,000.00 |
| Dec 31, 2022 | 8.47 Mn |
| Sep 30, 2020 | 859,000.00 |